Latest Insider Transactions at Cytom X Therapeutics, Inc. (CTMX)
This section provides a real-time view of insider transactions for Cytom X Therapeutics, Inc. (CTMX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CytomX Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CytomX Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2023
|
Sean A. Mc Carthy CEO |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+20.96%
|
-
|
|
Feb 02
2023
|
Christopher Ogden Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+39.5%
|
-
|
|
Feb 02
2023
|
Lloyd A Rowland General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+25.48%
|
-
|
|
Feb 02
2023
|
Jeffrey B Landau Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+36.13%
|
-
|
|
Jul 20
2022
|
Amy C. Peterson EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
7,463
-10.64%
|
$7,463
$1.42 P/Share
|
|
Jul 20
2022
|
Jeffrey B Landau Chief Business Officer |
SELL
Open market or private sale
|
Direct |
4,206
-12.04%
|
$4,206
$1.42 P/Share
|
|
Jul 20
2022
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
14,911
-4.88%
|
$14,911
$1.42 P/Share
|
|
Jul 20
2022
|
Lloyd A Rowland General Counsel |
SELL
Open market or private sale
|
Direct |
5,602
-11.37%
|
$5,602
$1.42 P/Share
|
|
Jul 20
2022
|
Alison L. Hannah Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,602
-14.94%
|
$5,602
$1.42 P/Share
|
|
Jul 20
2022
|
Carlos Campoy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,949
-8.99%
|
$3,949
$1.42 P/Share
|
|
Jul 19
2022
|
Amy C. Peterson EVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+22.18%
|
-
|
|
Jul 19
2022
|
Jeffrey B Landau Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,250
+24.36%
|
-
|
|
Jul 19
2022
|
Sean A. Mc Carthy CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+11.57%
|
-
|
|
Jul 19
2022
|
Lloyd A Rowland General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+23.33%
|
-
|
|
Jul 19
2022
|
Alison L. Hannah Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+28.57%
|
-
|
|
Jul 19
2022
|
Carlos Campoy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+25.46%
|
-
|
|
May 09
2022
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
90,931
+14.99%
|
$0
$0.94 P/Share
|
|
Feb 02
2022
|
Sean A. Mc Carthy CEO |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+30.01%
|
-
|
|
Feb 02
2022
|
Carlos Campoy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+43.76%
|
-
|
|
Feb 02
2022
|
Alison L. Hannah Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+50.0%
|
-
|
|
Feb 02
2022
|
Lloyd A Rowland General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+39.62%
|
-
|
|
Feb 02
2022
|
Amy C. Peterson EVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+46.29%
|
-
|
|
Aug 11
2021
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
92,113
+47.97%
|
$92,113
$1.13 P/Share
|
|
Jun 16
2021
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Indirect |
100,000
-51.78%
|
$700,000
$7.04 P/Share
|
|
Jun 14
2021
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
40
+0.25%
|
$40
$1.04 P/Share
|
|
May 31
2021
|
Amy C. Peterson EVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+34.08%
|
$19,920
$6.09 P/Share
|
|
May 31
2021
|
Carlos Campoy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,320
+34.08%
|
$19,920
$6.09 P/Share
|
|
Mar 31
2021
|
Sean A. Mc Carthy CEO |
SELL
Open market or private sale
|
Direct |
100,000
-32.58%
|
$700,000
$7.49 P/Share
|
|
Mar 31
2021
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+24.58%
|
$100,000
$1.13 P/Share
|
|
Dec 23
2020
|
Sean A. Mc Carthy CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+32.58%
|
$100,000
$1.13 P/Share
|
|
Nov 30
2020
|
Carlos Campoy Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,101
+50.0%
|
$18,606
$6.39 P/Share
|
|
Nov 30
2020
|
Sean A. Mc Carthy CEO |
BUY
Grant, award, or other acquisition
|
Direct |
930
+0.86%
|
$5,580
$6.39 P/Share
|
|
Nov 30
2020
|
Amy C. Peterson EVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,101
+50.0%
|
$18,606
$6.39 P/Share
|
|
Sep 30
2019
|
Sean A. Mc Carthy CEO |
SELL
Bona fide gift
|
Direct |
4,500
-36.56%
|
-
|